- Home
- GROW vs NSRX Comparison
GROW vs NSRX Comparison
Compare GROW & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | NSRX |
|---|---|---|
| Founded | 1968 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 38.9M |
| IPO Year | 1995 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GROW | NSRX |
|---|---|---|
| Price | $3.02 | $3.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 11.0K | 10.2K |
| Earning Date | 05-11-2026 | 03-25-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ 900.00 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $14,399,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.09 | ★ N/A |
| Revenue Growth | ★ 32.77 | N/A |
| 52 Week Low | $2.23 | $1.98 |
| 52 Week High | $3.65 | $9.50 |
Technical Indicators
Market Signals| Indicator | GROW | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.24 | 52.07 |
| Support Level | $3.10 | $2.90 |
| Resistance Level | $3.41 | $4.49 |
| Average True Range (ATR) | 0.09 | 0.33 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 56.14 | 61.05 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.